Sogroya Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved diagnosis of adult growth hormone deficiency, expansion of endocrinology specialty care, increased availability of recombinant hormone therapies, growing awareness of adult ghd symptoms, adoption of injectable hormone replacement.

The growth in the forecast period can be attributed to increasing demand for simplified hormone replacement regimens, rising focus on quality-of-life improvement, expansion of home-based hormone therapy, growing investments in long-acting biologics, increasing physician preference for weekly dosing. Major trends in the forecast period include increasing adoption of long-acting growth hormone replacement, rising demand for weekly adult ghd therapies, growing focus on treatment adherence improvement, expansion of pegylated hormone technologies, enhanced emphasis on patient convenience.

The growing demand for hormone replacement therapy (HRT) is expected to drive the expansion of the Sogroya market going forward. HRT is a treatment used to replace hormones such as estrogen and progesterone to address symptoms related to menopause or other hormonal imbalances. The increasing adoption of HRT is fueled by a higher prevalence of hormonal deficiencies, greater awareness of its benefits, and advancements in medical therapies that improve accessibility and effectiveness for managing conditions like menopause and growth hormone deficiency. Sogroya contributes to HRT by offering a once-weekly treatment for patients with growth hormone deficiency, helping restore normal hormone levels, improve physical function, and enhance quality of life with a convenient dosing schedule. For instance, in October 2025, the National Health Service (NHS), a UK-based government body, reported that approximately 14.7 million HRT items were prescribed, representing an 11% increase compared with 2023/24. Therefore, the rising demand for hormone replacement therapy is driving the growth of the Sogroya market.

Increasing pharmaceutical industry investment is expected to further propel the Sogroya market. Pharmaceutical investment refers to funds allocated toward research and development, clinical trials, manufacturing, and commercialization to create, develop, and market new therapies. This investment is rising due to the growing demand for innovative biologic treatments, encouraging companies to dedicate more resources to advanced research and development to meet unmet medical needs. Sogroya supports such investment by providing a differentiated once-weekly growth hormone therapy that strengthens company portfolios, expands market opportunities, and promotes continued funding for innovative endocrine treatments. For instance, in December 2024, the Centers for Medicare & Medicaid Services (CMS) reported that U.S. healthcare expenditures rose 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per individual. Therefore, increasing pharmaceutical investment is driving the growth of the Sogroya market.

Key companies in the Sogroya market are focusing on obtaining regulatory approvals to expand treatment indications and improve patient access. Regulatory approvals are official authorizations by government agencies that confirm a drug’s safety, efficacy, and quality before it can be marketed or prescribed. For example, in April 2023, Novo Nordisk A/S, a Denmark-based pharmaceutical company, received FDA approval for Sogroya for treating children aged 2.5 years and older with growth hormone deficiency, making it the first once-weekly growth hormone therapy available for both pediatric and adult patients. This treatment offers subcutaneous injections once a week, providing a convenient alternative to daily injections. The approval was based on the phase 3 REAL4 study, which demonstrated comparable height velocity outcomes between Sogroya and daily somatropin, with common side effects including nasopharyngitis, headache, and injection site reactions.

Major companies operating in the sogroya market are Novo Nordisk A/S.

North America was the largest region in the sogroya market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sogroya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sogroya market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the sogroya market by increasing costs of imported pegylation agents, biologic production inputs, pre-filled syringe components, and cold-chain transportation systems. Adult endocrinology practices in North America and Europe are most affected due to reliance on imported biologics, while Asia-Pacific faces cost pressures in manufacturing and distribution. These tariffs are increasing therapy costs and slowing adoption in price-sensitive markets. However, they are also encouraging regional biologics manufacturing, localized syringe production, and long-term strengthening of pharmaceutical supply chains.

The sogroya market research report is one of a series of new reports that provides sogroya market statistics, including sogroya industry global market size, regional shares, competitors with a sogroya market share, detailed sogroya market segments, market trends and opportunities, and any further data you may need to thrive in the sogroya industry. This sogroya market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sogroya (somapegsomatropin) is a long-acting growth hormone therapy used to treat adults with growth hormone deficiency (GHD). It provides the benefits of growth hormone replacement with the convenience of once-weekly injections, enhancing patient adherence to treatment.

The primary indications for Sogroya include adult growth hormone deficiency and pediatric growth hormone deficiency. Adult growth hormone deficiency (AGHD) is a condition in which the body produces insufficient growth hormone (GH) after the normal growth period in childhood. Sogroya is available in subcutaneous injectable and prefilled syringe formulations and is distributed through retail and online pharmacies. End users include hospitals, clinics, and ambulatory care centers.

The sogroya market consists of sales of syringes and needles, sterile wipes, alcohol swabs, and sharps containers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.